Gritstone Bio GRTS is a clinical-stage biotechnology company focused on developing vaccines targeting multiple indications, including cancer. In the past week, the company’s stock lost 57.5%. This ...
In a report released yesterday, Kaveri Pohlman from BTIG maintained a Buy rating on Gritstone Oncology (GRTS – Research Report), with a price target of $20.00. The company’s shares closed last Friday ...
The average one-year price target for Gritstone Bio (NASDAQ:GRTS) has been revised to 10.71 / share. This is an increase of 22.09% from the prior estimate of 8.77 dated August 31, 2023. The price ...
Gritstone bio (NASDAQ:GRTS) was downgraded by both Jones Research and B. Riley on Wednesday, the day after the stock cratered in the wake of mixed data for Gritstone’s GRANITE cancer vaccine and news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results